Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Vaccination for Atherosclerosis (2010)

  • Authors:
  • USP affiliated authors: PEREIRA, ROSA MARIA RODRIGUES - FM
  • USP Schools: FM
  • DOI: 10.1007/s12016-009-8145-y
  • Subjects: INFLAMAÇÃO; ARTERIOSCLEROSE (IMUNOLOGIA); VACINAÇÃO
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s12016-009-8145-y (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Clinical Reviews in Allergy and Immunology

    ISSN: 1080-0549

    Citescore - 2017: 5.02

    SJR - 2017: 0.967

    SNIP - 2017: 1.577


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM2126317-10BCSEP 067 2010
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      CARVALHO, Jozélio Freire de; PEREIRA, Rosa Maria R.; SHOENFELD, Yehuda. Vaccination for Atherosclerosis. Clinical Reviews in Allergy & Immunology, Totowa, v. 38, n. 2, p. 135-140, 2010. Disponível em: < http://www.springerlink.com/content/t8v06202kn3264w2/fulltext.pdf > DOI: 10.1007/s12016-009-8145-y.
    • APA

      Carvalho, J. F. de, Pereira, R. M. R., & Shoenfeld, Y. (2010). Vaccination for Atherosclerosis. Clinical Reviews in Allergy & Immunology, 38( 2), 135-140. doi:10.1007/s12016-009-8145-y
    • NLM

      Carvalho JF de, Pereira RMR, Shoenfeld Y. Vaccination for Atherosclerosis [Internet]. Clinical Reviews in Allergy & Immunology. 2010 ; 38( 2): 135-140.Available from: http://www.springerlink.com/content/t8v06202kn3264w2/fulltext.pdf
    • Vancouver

      Carvalho JF de, Pereira RMR, Shoenfeld Y. Vaccination for Atherosclerosis [Internet]. Clinical Reviews in Allergy & Immunology. 2010 ; 38( 2): 135-140.Available from: http://www.springerlink.com/content/t8v06202kn3264w2/fulltext.pdf

    Referências citadas na obra
    Jara LJ, Medina G, Vera-Lastra O, Amigo MC (2006) Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 5:195–201
    Sherer Y, Shoenfeld Y (2002) Atherosclerosis. Ann Rheum Dis 61:97–99
    Kannel WB, Castelli WP, Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 90:85–91
    Asztalos BF, Schaefer EJ (2003) HDL in atherosclerosis: actor or bystander? Atheroscler Suppl 4:21–29
    Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegård J (2006) Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis 188:160–166
    Frostegård J, Tao W, Georgiades A, Råstam L, Lindblad U, Lindeberg S (2007) Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. Nutr Metab (Lond) 4:7
    Elkan AC, Sjöberg B, Kolsrud B, Ringertz B, Hafström I, Frostegård J (2008) Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. Arthritis Res Ther 10:R34
    Su J, Hua X, Concha H, Svenungsson E, Cederholm A, Frostegård J (2008) Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatology (Oxford) 47:1144–1150
    Rajaiah R, Moudgil KD (2009) Heat-shock proteins can promote as well as regulate autoimmunity. Autoimmun Rev 8:388–393
    Okada T, Ayada K, Usui S, Yokota K, Cui J, Kawahara Y et al (2007) Antibodies against heat shock protein 60 derived from Helicobacter pylori: diagnostic implications in cardiovascular disease. J Autoimmun 29:106–115
    Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemiology, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325–330
    Conti F, Rezai S, Valesini G (2008) Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 8:124–128
    Tsonis IA, Avrameas S, Moutsopoulos HM (2007) Autoimmunity and pathophysiology. J Autoimmun. 29:203–205
    Gero S, Gergely J, Jakab L, Szekely J, Virag S, Farkas K, Czuppon A (1959) Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein. Lancet 2:6–7
    Gero S (1967) Some data on the influence of cholesterol atherosclerosis by immunological means. Rev Atheroscler (Paris) 9(Suppl 1):194–198
    Siegler PE (1967) Some immunological aspects of atherosclerosis. Rev Atheroscler (Paris) 9(Suppl 1):199
    Bailey Jm, Tomar R (1965) Lipoprotein immunization and induced atherosclerosis in rabbits. 1. Cockerel beta-lipoproteins as antigens. J Atheroscler Res 5:203–214
    Palinski W, Tangirala RK, Miller E, Young SG, Witztum JL (1995) Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 15:1569–1576
    Ameli S, Hultgårdh-Nilsson A, Regnström J, Calara F, Yano J, Cercek B et al (1996) Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16:1074–1079
    Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, Nilsson J (2003) Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol 23:879–884
    Bailey JM, Bright R, Tomar R (1964) Immunization with a synthetic cholesterol-ester antigen and induced atherosclerosis in rabbits. Nature 201:407–408
    Bailey JM, Bright R, Tomar R, Butler J (1994) Anti-atherogenic effects of cholesterol vaccination. Biochem Soc Trans 22:433S
    Alving CR, Swartz GM Jr, Wassef NM, Ribas JL, Herderick EE, Virmani R et al (1996) Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J Lab Clin Med 127:40–49
    Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR (2003) Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160–167
    Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD et al (2000) Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20:2106–2112
    Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U (2003) The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169:113–120
    Ryan US, Rittershaus CW (2006) Vaccines for the prevention of cardiovascular disease. Vascul Pharmacol 45:253–257
    Rittershaus CW (2007) Vaccines for cholesterol management. World J Surg 31:690–694
    Gaofu Q, Rongyue C, Dan M, Xiuyun Z, Xuejun W, Jie W et al (2006) Asparaginase display of human cholesteryl ester transfer protein (CETP) B cell epitopes for inducing high titers of anti-CETP antibodies in vivo. Prot Peptide Letters 13:149–154
    Gaofu Q, Jun L, Xiuyun Z, Wentao L, Jie W, Jingjing L (2005) Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci 77:2690–2702
    Gaofu Q, Jun L, Xin Y, Wentao L, Jie W, Xiuyun Z et al (2005) Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol 45:591–598
    Gaofu Q, Dan M, Jie W, Liao Z, Li Z, Roque RS, Jingjing L (2004) Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine 22:3187–3194
    Lamb DJ, El-Sankary W, Ferns GA (2003) Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 167:177–185
    Alard JE, Dueymes M, Youinou P, Jamin C (2007) Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. Autoimmun Rev 6:438–443
    Bassi N, Ghirardello A, Iaccarino L, Zampieri S, Rampudda ME, Atzeni F, Sarzi-Puttini P, Shoenfeld Y, Doria A (2007) OxLDL/beta2GPI-anti-oxLDL/beta2GPI complex and atherosclerosis in SLE patients. Autoimmun Rev 7:52–58
    Schett G, Xu Q, Amberger A, Van der Zee R, Recheis H, Willeit J et al (1995) Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 96:2569–2577
    Lamb DJ, Tickner ML, Dreux AC, El-Sankary W, Hourani SM, Eales-Reynolds LJ et al (2004) Impairment of vascular function following BCG immunisation is associated with immune responses to HSP-60 in the cholesterol-fed rabbit. Atherosclerosis 172:13–20
    Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J (2002) Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 40:1333–1338
    Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874
    Bixel MG, Petri B, Khandoga AG, Khandoga A, Wolburg-Buchholz K, Wolburg H et al (2007) A CD99-related antigen on endothelial cells mediates neutrophil but not lymphocyte extravasation in vivo. Blood 109:5327–5336
    van Wanrooij EJ, de Vos P, Bixel MG, Vestweber D, van Berkel TJ, Kuiper J (2008) Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice. Cardiovasc Res 78:590–596
    Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R et al (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108–2116
    Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK (2007) DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 27:1095–1100
    Hauer AD, van Puijvelde GH, Peterse N, de Vos P, van Weel V, van Wanrooij EJ et al (2007) Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 27:2050–2057
    Hauer AD, Uyttenhove C, de Vos P, Stroobant V, Renauld JC, van Berkel TJ et al (2005) Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112:1054–1062
    Madjid M, Naghavi M, Litovsky S, Casscells SW (2003) Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation 108:2730–2736
    Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W (2000) Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 102:3039–3045
    Siscovick DS, Raghunathan TE, Lin D, Weinmann S, Arbogast P, Lemaitre RN et al (2000) Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 152:674–677
    Gurevich VS (2005) Influenza, autoimmunity and atherogenesis. Autoimmun Rev 4:101–105
    Zhu J, Quyyumi AA, Norman JE, Costello R, Csako G, Epstein SE (2000) The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis 182:1583–1587
    Burnett MS, Zhu J, Miller JM, Epstein SE (2003) Effects of hepatitis A vaccination on atherogenesis in a murine model. J Viral Hepatitis 10:433–436
    Scannapieco FA, Bush RB, Paju S (2003) Associations between periodontal disease and risk for atherosclerosis, cardiovascular disease, and stroke. A systematic review. Ann Periodontol 8:38–53
    Koizumi Y, Kurita-Ochiai T, Oguchi S, Yamamoto M (2008) Nasal immunization with Porphyromonas gingivalis outer membrane protein decreases P. gingivalis-induced atherosclerosis and inflammation in spontaneously hyperlipidemic mice. Infect Immun 76:2958–2965
    Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M, Gottwik M, Altmann E, Seidel F, Rox J, Höffler U, Neuhaus KL, Senges J, Working Group of Leading Hospital Cardiologists (2003) Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 107:1253–1259
    Joensen JB, Juul S, Henneberg E, Thomsen G, Ostergaard L, Lindholt JS (2008) Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 196:937–942
    Sawayama Y, Tatsukawa M, Kikuchi K, Maeda S, Ohnishi H, Furusyo N, Hayashi J (2007) Effect on carotid atherosclerosis of probucol plus levofloxacin for Chlamydia pneumoniae infection. J Infect Chemother 13:92–98
    Sherer Y, Shoenfeld Y (2005) Immunomodulation for treatment and prevention of atherosclerosis. Autoimmun Rev 1:21–27
    Nilson J, Hansson GK, Shah PK (2005) Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 25:18–28